STAT+: Key data on a new class of cardio drugs are coming

STAT PlusNewsletterThe Readout Key data on a new class of cardio drugs are coming GSK’s shingles vaccine, new financial investment in women’s health, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenAug. 26, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We are thinking of Dolly Parton, who made a lasting impact not only in music and culture, but also in science. During the Covid-19 pandemic, she donated $1 million to Vanderbilt University Medical Center to help speed the development of Moderna’s vaccine.pharma Advertisement Key data on a new class of cardio drugs are coming Several large pharma companies are betting that targeting a particle called lipoprotein(a) will be the next big advance in cardiovascular medicine.

We’ll soon find out how well the approach works. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.

You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended AI Prognosis August 26, 2026 STAT Plus: AI biotech Insitro’s Daphne Koller on how to speed up clinical trials Biotech August 25, 2026 STAT Plus: After a years-long slump, Massachusetts biopharma sector has come roaring back in 2026 Advertisement The Readout August 24, 2026 STAT Plus: Lady Gaga and her fiancé launch a biotech startup Biotech August 24, 2026 STAT Plus: FDA pauses Regenxbio gene therapy trial again due to safety concerns Special Report August 24, 2026 STAT Plus: Inside Moderna and Merck’s cancer vaccine triumph Subscriber Picks